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Evidencea b s t r a c t
Radiotherapy interventions are rapidly evolving and improving, holding promise for better patient out-
comes, yet at the possible detriment of higher societal costs. The ESTRO-HERO value-based radiotherapy
project aims to develop a framework defining and assessing the value of radiotherapy innovations, to
support clinical implementation and equitable access, within a sustainable healthcare system.
 2021 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 160 (2021) 236–239 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Radiotherapy is one of the cornerstones of multidisciplinary
cancer care, required by at least one out of two cancer patients,
and improving local control, survival and quality-of-life [1–3].
Due to the increasing cancer incidence, the numbers of patients
that will need radiotherapy are expected to further rise dramati-
cally in the years to come [1,4]. Unfortunately, radiotherapy access
remains far from optimal, especially in low-and middle-income
countries, mainly due to the lack in human and capital resources
[1,5]. Disturbingly, underutilisation also occurs in many high-
income countries, in spite of better resource availability. In Europe,
for instance, at least a quarter of the cancer patients who should
receive radiotherapy, do not [3].
Over the past decades, radiotherapy has been evolving, innovat-
ing and improving at a rapid pace, holding promise for better
patient outcomes [6]. This evolution however harbours the risk
of a growing divide between the swift uptake of new radiotherapy
interventions, even without strong evidence in some cases, and a
remaining underutilisation of radiotherapy, negatively impacting
the outcome of cancer patients. While imposing a choice between
implementing innovation and providing optimal access is not at
stake, it is mandatory to find common ground on how to define
the real value of radiotherapy innovations, in order not to waste
limited budget, and resources, further hampering access and the
sustainability of health system financing.Radiotherapy innovation
Innovative radiotherapy results from the evolution in radiation
technology, but also from the integration of advanced imaging
before and during radiotherapy, and the availability of high-
performing computer systems [6]. This has lead to the develop-
ment of a broad range of new techniques, intensity-modulated
(IMRT), stereotactic body (SBRT) and adaptive (ART) radiotherapy
to name but a few. The increased potential of novel technologies
and techniques to target the tumor, while limiting the dose –
and toxicity – to the surrounding organs, has further paved the
way to the adoption of new irradiation schedules (such as
hypofractionation – fewer but higher doses per treatment) and
new indications (e.g. oligometastatic disease, combinations with
new systemic agents) [7–10].
Some innovations represent major changes with the potential
to impact outcome in a stepswise fashion, think of new dose frac-
tionation schedules, new radiotherapy-drug combinations or tech-
nologies with distinct biological, physical or imaging properties
such as particle therapy or MR-guided radiotherapy. As in other
aspects of cancer, innovation may however not be seen as a major
breakthrough at onset, yet present itself as a series of smaller,
incremental, changes of which the real impact gradually becomes
evident over time [11,12]. Examples of the latter could be new
immobilisation devices or computer planning algorithms.
Radiotherapy is unique in that the translation of innovation into
improvements in outcomes – especially decreased toxicity and the
consequential impact on quality-of-life – may only become appar-
ent months to years after therapy. In addition, new radiotherapy
techniques and technologies often require specific training, leading
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experience of the multidisciplinary team, and embedded quality
assurance processes [11]. Both factors translate into a time-
dependency of radiotherapy innovations, where formal evidence
of improved outcome may take long to mature.How to support radiotherapy innovation
Innovation is taking place in all aspects of cancer care – often
with shorthening life cycles – which, along with the increasing
incidence and burden of cancer, has resulted in an unprecedented
growth of cancer care expenditure over the past decades [13,14]. In
view of the need for financial sustainability, healthcare systems
should focus on the introduction of those new cancer care inter-
ventions that are high-quality, efficient and equitable, by using
dedicated health technology assessment (HTA), reimbursement
and policy decisions [12,15]. Moreover, acknowledging that inno-
vations should make a meaningful difference to patients, greater
involvement of patients and caregivers in defining and assessing
their value is needed. [12].
Alas, a strong HTA approach for innovation with medical
devices, consistent with the one used for new (cancer) drugs, has
yet to be developed, accepted and implemented in Europe
[11,16]. This is not trivial. Innovative radiotherapy technologies
and techniques may come at a cost, due to higher initial invest-
ments and the additional time and resources required to enable
their safe and high-quality implementation and utilization [17].
In contrast, innovation in the preparation (e.g. through increasingly
automated planning) and the delivery of radiotherapy may in turn
facilitate optimized workflows, increase productivity and reduce
treatment duration (such as through hypofractionation), which
may counteract increasing costs.
The radiotherapy reimbursement systems in place to date do
not sufficiently recognize the dynamic evolution of radiotherapy
practice [18]. One illustrative example is that the majority of
national reimbursement systems still support a fraction-based
model, which is detrimental to the uptake of evidence-based
hypofractionated radiotherapy schedules. Ideally, evidence on clin-
ical benefit and cost-effectiveness, in addition to data on safety, of
any new radiotherapy intervention should be rewarded by reim-
bursement that promotes its adoption in clinical practice. Data
can be derived from prospective clinical trials, but due to the speci-
ficities of radiotherapy and the broad range in treatment indica-
tions being addressed, a blended approach to evidence
generation, including real-world data should be considered
[15,16,19].
While there is a tendency to propagate innovations on the pure
belief that new is better, even if evidence remains limited and
uncertain, the radiotherapy community – along with all relevant
stakeholders including patients – should take up its responsibility
and not accept a substandard evidence-base and small benefits of
new radiotherapy interventions at whatever cost. In contrast, a
strong healthcare system should embrace the delivery of innova-
tive technologies, techniques and treatments that provide real
value to the patients, at fair prices [15].Value-based healthcare, a radiotherapy perspective
According to Porter, value-based healthcare (VBHC) is defined
as the health outcomes (that matter most to patients) achieved
per dollar spent over the total cycle of care [20]. Taking this notion
of VBHC forward, value scales have been developed to appraise
both the strength of clinical evidence and the expected added ben-
efit for the patient of a particular intervention, whereas traditional
cost-effectiveness or cost-utility tools tend to focus on whether an237intervention meets a pre-defined threshold for cost per outcome
[21].
With respect to value, changes in both outcomes and costs will
enhance value. A pragmatic example to understand this is
hypofractionation, a proven treatment approach in specific breast
or prostate cancer indications [7,8,22]. Reducing the number of
radiotherapy fractions, but achieving the same health outcomes
across the life cycle, would be a high value intervention given
the reduction in resource costs of treatment delivery and in treat-
ment burden with potential quicker return to previous activities.
Furthermore, some hypofractionated treatments may result in
reduced toxicities, which over the cancer care cycle is likely to
decrease healthcare and societal costs by lower need for interven-
tions to manage these complications, or to enable individuals to
partake in work and day to day activities [23,24].
As higher costs do not guarantee improved outcomes [25], ini-
tiatives have sought to define high and low value cancer care.
These include prioritisation exercises by multi-stakeholder groups
defining low-value or unsafe care practices in particular country or
continent contexts, such as the Choosing Wisely campaigns [26–
28], or the development of value appraisal tools for new interven-
tions. With respect to the latter, the ESMO Magnitude of Clinical
Benefit Scale, the ASCO Value Framework and the NCCN Blocks
are the dominant scales that have been used when considering
the value of oncology interventions, specifically drug treatments
[29–31]. These value frameworks use a pre-defined rigorous
approach to appraising evidence and aim to provide transparency
for various stakeholders around the perceived benefits and
required standards of new therapies. Importantly, they provide
benchmarks for the level of evidence and magnitude of benefit to
be considered for reimbursement, which should ultimately ensure
evidence on new interventions is generated keeping the relevant
outcomes in mind.
Some caveats to the use of these tools have however been
raised: not all drugs appraised to be high-value also deliver the
expected benefit in practice [32,33], nor do these frameworks
grasp all intricacies that come along with surgical or radiation
oncology [11]. In the latter, for instance, there are a broader range
of outcomes to consider over and above overall survival or quality-
of-life. These may include local control and organ preservation, but
also functional aspects such as improvement in swallow function
or conservation of speech for those with mouth cancers, or time
to return to work. The appropriateness of these endpoints may
vary significantly depending on the type of innovation and its
intent.
Porter proposed to group outcomes into three tiers [20]. Follow-
ing the same concept, clinical outcomes, specifically pertaining to
the context of radiation therapy, have been suggested [34]. Tier 1
considers the health status achieved following treatment, incorpo-
rating both survival and the degree of health recovery, which for
radiotherapy may include local control and functional outcome.
Tier 2 focuses on the process of recovery, the time required to
achieve remission or return to normal activities, and the burden
of treatment on the individual with respect to acute toxicities
and frequency or length of treatment. Tier 3 considers the sustain-
ability of health or long-term consequences of care, including
recurrences, sustained functional outcomes, long-term toxicities,
complications and quality-of-life.
Ultimately, studies on new cancer interventions, be it drugs or
loco-regional treatments, should not only consider the relevant
outcomes depending on the type of intervention and the magni-
tude or degree of benefit [35], but should also use the right trial
design to generate the evidence to support the given treatment
modality, technology or technique. Indeed, innovations that can
potentially improve outcomes in a stepwise fashion are likely to
necessitate more robust prospective or randomised evaluation
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life; whereas this may not hold for innovations which represent
incremental improvements and seek to improve efficiency, safety
and usability. Evidence generation may therefore span from ran-
domised controlled trials over pragmatic study concepts to real-
world data collection, e.g. in a context of coverage with evidence
development programs [12,15,36,37]. Whereas real-world data
undoubtly have an increasing role to play, particularly with respect
to understanding long-term patient outcomes, adverse events and
costs of care, their interpretation is very broad and not all of
homogenous quality, hence guidance on what constitutes high-
quality observational data is needed [38,39].
Finally, two other aspects are important to consider in VBHC,
not in the least in the context of loco-regional cancer treatments
such as radiotherapy. One is the notion of operator skills or provi-
der quality, which may not only impact outcome, but also the
resources required to deliver treatment. For that reason, one
should incorporate aspects of health service delivery, such as
resource use and related costs, into the evidence development pro-
cess from the outset [11]. The costing part of the value equation
has been largely neglected by the available oncology value tools
and has been subject to limited evaluation to date. Yet it is extre-
mely important in the field of radiation oncology where many
studies have a non-inferiority design with interventions designed
to achieve more efficient and cost-effective practices of care, with-
out necessarily quantifying this or specifying the degree of effect
sought.
ESTRO-HERO value-based healthcare project
Under the auspices of the Health Economics in Radiation Oncol-
ogy programme of the European Society for Radiotherapy and
Oncology (ESTRO-HERO) [40], a new project is launched aiming
to develop a robust framework for the appraisal of radiation oncol-
ogy innovations. As described, there are several conceptual chal-
lenges to achieving this goal [11,34]. Three key areas that need
exploration and consensus building will be addressed as part of a
multidisciplinary programme in order to ensure a framework that
is evidence-informed, robust and able to handle the significant
heterogeneity that exists within radiation oncology (Fig. 1).
1. To define and categorise the spectrum of innovations in radiation
oncology:Fig. 1. ESTRO-HERO value-b
238This work-package will provide a method for classifying radio-
therapy interventions. It will first categorise them broadly into
technologies, techniques and treatments, before considering
whether they represent stepwise or incremental innovations. This
classification is crucial given the vast heterogeneity and volume of
radiotherapy innovations that presently exists;
2. To define the outcomes supporting the implementation of radio-
therapy innovations:
This work-package will focus on generic and tumourtype-
agnostic outcomes relevant for radiotherapy. Clinical as well as
patient-centred outcomes, along with economic outcomes –
including operational and quality aspects – will be considered
[41,42]. Whilst the HERO-VBHC project will not seek to develop
or define new (sets of) outcome measures for specific tumour
types, it will define which outcomes should be prioritised for
new radiotherapy interventions, and categorise the diverse out-
comes into tiers [11,34]. The evolving concepts of curative versus
palliative treatment intent will also be considered to aid the
categorisation;
3. To define what magnitude of benefit and level of evidence is needed
to support the clinical implementation of a particular radiotherapy
intervention:
This work-package will link the previous two by addressing the
major conceptual challenge of combining the minimum benefit
required and the minimum level of evidence needed to support
the implementation of a particular radiotherapy intervention.
The benefit will be determined by considering clinical, patient-
centred and economic outcomes and the magnitude of benefit in
each domain. In addition, for each intervention type the acceptable
level of evidence will be defined and weighted according to the
strength of the evidence.
Integrating all above aspects will allow to build a value-based
framework for appraising radiotherapy innovations.
It is obvious that developing a value-based framework for radi-
ation oncology, core in ESTRO’s vision, will necessitate collabora-
tion of all involved in the radiotherapy care pathway including
radiation oncologists, physicists, and radiation therapists [43]. It
is also obvious that the input of patients will be invaluable in the
definition and categorisation of the relevant outcomes and the
minimal benefit that is deemed worthwhile [41,42]. Similarly,ased healthcare project.
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cians will be needed to define the required levels of evidence and
for building the final value-based framework. While the ESTRO is
committed to support and drive this initiative, endorsement from
the multidisciplinary oncology community at large, and from a
broad range of stakeholders involved in the treatment of cancer
patients with radiotherapy, will be sought to help develop this
project.
In conclusion, in an era of enhanced scrutiny on how to intro-
duce innovative healthcare interventions into daily practice and
to define their value, the radiation oncology community, supported
by a broad group of stakeholders in the field of multidisciplinary
oncology, will launch a project to define a VBHC framework consid-
ering the specificities of radiation oncology in terms of types of
interventions and treatment intent, outcomes generated and evi-
dence required. The HERO-VBHC project aims to develop such a
framework in keeping the already existing tools and acknowledg-
ing the expertise that has been developed in this field.
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